Regeneron and Sanofi Announce that Dupilumab Used with Topical Corticosteroids (TCS) was Superior to Treatment with TCS Alone in Long-term Phase 3 Trial in Inadequately Controlled Moderate-to-Severe Atopic Dermatitis Patients
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Don’t see a project related to the catalyst you care about?